Audentes Therapeutics (BOLD) with $35 Target Got Analyzed By Chardan Capital.

June 27, 2018 - By Ira Colvard

What Price Target Has Chardan Capital Given Audentes Therapeutics (BOLD)

Equity analysts at Chardan Capital has Neutral rating and has target price of $35 on BOLD’s shares. On Tuesday, 26 June a coverage started with Audentes Therapeutics (BOLD)‘s stock.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Coverage

A total of 5 analysts rate Audentes Therapeutics (BOLD) as follows: 3 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 60% are bullish. (BOLD) has 10 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Thursday, May 17 the stock has “Buy” rating by H.C. Wainwright. The stock rating was maintained by William Blair with “Buy” on Thursday, January 4. On Monday, February 12 the firm earned “Hold” rating by Mizuho. On Friday, March 9 the firm earned “Buy” rating by H.C. Wainwright. On Thursday, January 11 the rating was maintained by H.C. Wainwright with “Buy”. On Thursday, January 4 the company was maintained by H.C. Wainwright. On Wednesday, February 7 the rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, May 2 H.C. Wainwright maintained the shares of BOLD in report with “Buy” rating.

The stock decreased 1.71% or $0.7 during the last trading session, hitting $40.32.Audentes Therapeutics, Inc. has 744,178 shares volume, 65.41% up from normal. BOLD is uptrending and has moved 142.34% since June 27, 2017. BOLD outperformed by 129.77% the S&P500.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) is awaited to reveal earnings on August, 9., Faxor reports. Analysts forecast $-0.77 EPS, which is $0.10 up or 11.49 % from 2017’s $-0.87 EPS. After $-0.74 EPS was announced previous quarter, analysts now see negative EPS growth of 4.05 % for Audentes Therapeutics, Inc..

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects.The firm is worth $1.48 billion. The firm is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy ; AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.Last it reported negative earnings. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar.

More recent Audentes Therapeutics, Inc. (NASDAQ:BOLD) news were posted by Benzinga.com, Globenewswire.com and Benzinga.com. The first one has “Benzinga’s Top Upgrades, Downgrades For June 26, 2018” as a title and was posted on June 26, 2018. The next is “Market Trends Toward New Normal in Audentes Therapeutics, Aqua Metals, BT Group, Mid-America Apartment …” on May 31, 2018. And last was posted on June 21, 2018, called “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street”.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.